化疗市场－全球产业规模、份额、趋势、机会和预测，按类型、适应症、剂型、给药途径、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球化疗市场价值为 82.6 亿美元，预计在预测期内将呈现令人印象深刻的成长，到 2030 年的复合年增长率为 8.51%。世界卫生组织 (WHO) 表示，癌症是全球第二大死因，2018 年造成约 960 万人死亡。鑑于癌症发生率的上升，对化疗药物的需求将会增加。化疗是一种癌症治疗方法，它利用强效化学物质瞄准并消除体内快速分裂的细胞。它已被证明能减少癌细胞数量、阻止癌症进展和缩小肿瘤。例如，根据 WHO 2025，国际癌症研究机构 (IARC) 报告全球癌症负担上升，服务不足的人受影响最大。一项针对 115 个国家的调查显示，大多数国家没有在全民健康覆盖范围内为优先癌症和安宁疗护提供足够的资金。研究结果强调了透过加强卫生系统投资来解决全球癌症治疗不平等问题的迫切需求。

化疗通常是单独或合併使用，是一种适用于多种癌症的多功能治疗方式。它可作为主要或唯一治疗手段，清除隐藏的癌细胞，并为患者接受放射治疗或手术等其他干预措施做好准备。化疗还可以透过选择性靶向癌细胞来缓解癌症相关的征兆和症状。

关键市场驱动因素

癌症发生率上升

主要市场挑战

治疗费用高昂

主要市场趋势

创新技术开发

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球化疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型（烷化剂、抗代谢物、抗肿瘤抗生素、荷尔蒙、单株抗体、其他）
  • 依适应症（肿瘤/癌症、骨髓疾病类型、免疫系统疾病、其他）
  • 按剂型（胶囊、锭剂、注射剂、其他）
  • 依给药途径（口服、肠胃外、其他）
  • 按最终使用者（医院、专科诊所、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美化疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲化疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太化疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲化疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲化疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购

第 13 章：全球化疗市场：SWOT 分析

第 14 章：竞争格局

• F. Hoffmann-La Roche Ltd.
• Mylan NV
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck & Co., Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

Global Chemotherapy Market was valued at USD 8.26 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.51% through 2030. Cancer, as stated by the World Health Organization (WHO), is the second leading cause of mortality worldwide, resulting in an estimated 9.6 million deaths in 2018. Given the rising cancer rates, there will be an increased demand for chemotherapy medications. Chemotherapy is a cancer treatment approach that utilizes potent chemicals to target and eliminate rapidly dividing cells within the body. It has proven efficacy in reducing cancer cell count, impeding cancer progression, and shrinking tumors. For instance, according to WHO 2025, the International Agency for Research on Cancer (IARC) reported a rising global cancer burden, with underserved populations most affected. A survey across 115 countries revealed that most do not adequately fund priority cancer and palliative care within universal health coverage. The findings underscore the urgent need to address cancer care inequities worldwide through stronger health system investments.

Chemotherapy, often administered alone or in combination, is a versatile treatment modality for a wide range of cancers. It serves as a primary or sole treatment, eliminating hidden cancer cells and preparing patients for other interventions such as radiation or surgery. It can be employed to alleviate cancer-related signs and symptoms by selectively targeting cancer cells.

Key Market Drivers

Rising Incidences of Cancers

The increasing prevalence of cancer is projected to drive the growth rate of the chemotherapy drug market. According to NIH 2025, incidence rates of certain cancers have risen among individuals under age 50. However, despite this increase, overall cancer-related deaths in younger populations have not shown a corresponding rise. This suggests improvements in early detection, treatment options, and awareness, highlighting the importance of continued research and personalized care for younger cancer patients. Chemotherapy, often used in conjunction with other cancer treatments, remains the predominant approach to cancer treatment. Neo-adjuvant chemotherapy refers to chemotherapy administered prior to surgery and radiation therapy to reduce tumor size, while adjuvant chemotherapy is administered after surgery or radiation therapy to further shrink the tumor.

Key Market Challenges

High Cost of Treatment

The high cost associated with chemotherapy drugs poses a significant obstacle to the growth of the market. High chemotherapy costs can create financial barriers for patients, leading to delayed or deferred treatment, non-adherence to prescribed regimens, and reduced treatment effectiveness. Patients with limited financial resources may face disparities in accessing chemotherapy treatments, exacerbating existing healthcare inequalities. High costs can influence patients' treatment decisions, potentially leading to suboptimal choices based on financial considerations rather than medical necessity. The financial strain of chemotherapy can lead to reduced treatment access, particularly for uninsured or underinsured patients. The shortage of skilled professionals and inadequate healthcare infrastructure in developing economies present challenges to the chemotherapy drug market. The side effects of these drugs, including heart problems, decreased red blood cell count, fatigue, weight loss, hair loss, diarrhea, reduced lung, kidney, and liver function, decreased bone density, and limited awareness among the public, act as restraints and further hinder the market.

Key Market Trends

Development of Innovative Technology

Chemotherapy has played a pivotal role in extending the lifespan of cancer patients, surpassing their expected survival by several years. The latest breakthrough in the field of chemotherapy involves the administration of specially designed nanoparticles containing cancer-fighting medications, which selectively target affected areas while sparing healthy cells. This innovative approach has demonstrated remarkable efficacy in eradicating malignant cells while preserving surrounding healthy tissue. By utilizing photon lasers, medical professionals are able to precisely monitor the release, duration, and distribution of these medication-loaded nanoparticles within the patient's body. Excitingly, the University of California, Los Angeles, is currently conducting a clinical trial to evaluate the effectiveness of this approach, which has shown promising outcomes in the treatment of early-stage cancer patients. With its imminent entry into the chemotherapeutic market, this groundbreaking technique holds great potential for transforming cancer treatment.

Key Market Players

• Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck & Co., Inc.

Report Scope:

In this report, the Global Chemotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chemotherapy Market, By Type:

• Alkylating Agents
• Anti-metabolites
• Anti-Tumor Antibiotics
• Hormones
• Monoclonal Antibodies
• Others

Chemotherapy Market, By Indication:

• Oncology/Cancer
• Bone Marrow Diseases
• Immune System Disorders
• Others

Chemotherapy Market, By Dosage Form:

• Capsule
• Tablets
• Injections
• Others

Chemotherapy Market, By Route of Administration:

• Oral
• Parenteral
• Others

Chemotherapy Market, By End User:

• Hospitals
• Specialty Clinics
• Others

Chemotherapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chemotherapy Market.

Available Customizations:

Global Chemotherapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chemotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Alkylating Agents, Anti-metabolites, Anti-Tumor Antibiotics, Hormones, Monoclonal Antibodies, Others)
  • 5.2.2. By Indication (Oncology/Cancer, Bone Marrow Diseasestype, Immune System Disorders, Others)
  • 5.2.3. By Dosage Form (Capsule, Tablets, Injections, Others)
  • 5.2.4. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.5. By End User (Hospitals, Specialty Clinics, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Chemotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Indication
  • 6.2.3. By Dosage Form
  • 6.2.4. By Route of Administration
  • 6.2.5. By End Users
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chemotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Dosage Form
      • 6.3.1.2.4. By Route of Administration
      • 6.3.1.2.5. By End Users
  • 6.3.2. Canada Chemotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Dosage Form
      • 6.3.2.2.4. By Route of Administration
      • 6.3.2.2.5. By End Users
  • 6.3.3. Mexico Chemotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Dosage Form
      • 6.3.3.2.4. By Route of Administration
      • 6.3.3.2.5. By End Users

7. Europe Chemotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Indication
  • 7.2.3. By Dosage Form
  • 7.2.4. By Route of Administration
  • 7.2.5. By End Users
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chemotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Dosage Form
      • 7.3.1.2.4. By Route of Administration
      • 7.3.1.2.5. By End Users
  • 7.3.2. United Kingdom Chemotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Dosage Form
      • 7.3.2.2.4. By Route of Administration
      • 7.3.2.2.5. By End Users
  • 7.3.3. Italy Chemotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Dosage Form
      • 7.3.3.2.4. By Route of Administration
      • 7.3.3.2.5. By End Users
  • 7.3.4. France Chemotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Dosage Form
      • 7.3.4.2.4. By Route of Administration
      • 7.3.4.2.5. By End Users
  • 7.3.5. Spain Chemotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Dosage Form
      • 7.3.5.2.4. By Route of Administration
      • 7.3.5.2.5. By End Users

8. Asia-Pacific Chemotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Indication
  • 8.2.3. By Dosage Form
  • 8.2.4. By Route of Administration
  • 8.2.5. By End Users
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Chemotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Dosage Form
      • 8.3.1.2.4. By Route of Administration
      • 8.3.1.2.5. By End Users
  • 8.3.2. India Chemotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Dosage Form
      • 8.3.2.2.4. By Route of Administration
      • 8.3.2.2.5. By End Users
  • 8.3.3. Japan Chemotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Dosage Form
      • 8.3.3.2.4. By Route of Administration
      • 8.3.3.2.5. By End Users
  • 8.3.4. South Korea Chemotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Dosage Form
      • 8.3.4.2.4. By Route of Administration
      • 8.3.4.2.5. By End Users
  • 8.3.5. Australia Chemotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Dosage Form
      • 8.3.5.2.4. By Route of Administration
      • 8.3.5.2.5. By End Users

9. South America Chemotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Indication
  • 9.2.3. By Dosage Form
  • 9.2.4. By Route of Administration
  • 9.2.5. By End Users
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Chemotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Dosage Form
      • 9.3.1.2.4. By Route of Administration
      • 9.3.1.2.5. By End Users
  • 9.3.2. Argentina Chemotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Dosage Form
      • 9.3.2.2.4. By Route of Administration
      • 9.3.2.2.5. By End Users
  • 9.3.3. Colombia Chemotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Dosage Form
      • 9.3.3.2.4. By Route of Administration
      • 9.3.3.2.5. By End Users

10. Middle East and Africa Chemotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Indication
  • 10.2.3. By Dosage Form
  • 10.2.4. By Route of Administration
  • 10.2.5. By End Users
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Chemotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Dosage Form
      • 10.3.1.2.4. By Route of Administration
      • 10.3.1.2.5. By End Users
  • 10.3.2. Saudi Arabia Chemotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Dosage Form
      • 10.3.2.2.4. By Route of Administration
      • 10.3.2.2.5. By End Users
  • 10.3.3. UAE Chemotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Dosage Form
      • 10.3.3.2.4. By Route of Administration
      • 10.3.3.2.5. By End Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Chemotherapy Market: SWOT Analysis

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd.
• 14.2. Mylan N.V.
• 14.3. Teva Pharmaceutical Industries Ltd.
• 14.4. Sanofi
• 14.5. Pfizer Inc.
• 14.6. GlaxoSmithKline plc
• 14.7. Novartis AG
• 14.8. Bayer AG
• 14.9. Eli Lilly and Company
• 14.10. Merck & Co., Inc.

15. Strategic Recommendations

16. About Us & Disclaimer